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PathwayMIR137, transcribed as themicroRNAmiR-137, is one of the leading candidate schizophrenia susceptibility genes
to arise from large genome-wide association studies (GWAS) of the disorder. Recent data suggest that miR-137
modulates the expression of other schizophrenia susceptibility genes. Although bioinformatic resources are
available with which to predict genes regulated by individual microRNA, there has been a lack of empirical
data on genome-wide gene expression changes following miR-137 manipulation. We have therefore performed
a genome-wide assessment of transcriptional changes in a human neural progenitor cell line after miR-137 over-
expression and inhibition in order to elucidate molecular pathways by which genetic perturbation of miR-137
could promote susceptibility to schizophrenia. Bioinformatically-predicted miR-137 targets showed a small but
highly signiﬁcant down-regulation following miR-137 over-expression. Genes that were signiﬁcantly down-
regulated in association with miR-137 over-expression were enriched for involvement in neuronal differentia-
tion. Differentially expressed genes that were conﬁrmed by qPCR included others at genome-wide signiﬁcant
risk loci for schizophrenia (MAD1L1 and DPYD) and BDNF. These data point to molecular pathways through
which genetic variation at theMIR137 locus could confer risk for schizophrenia.
© 2014 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Large-scale genome-wide association studies (GWAS) have identiﬁed
the chromosome 1 region containingMIR137 host gene (MIR137HG) as a
susceptibility locus for schizophrenia (Schizophrenia Psychiatric GWAS
Consortium, 2011; Ripke et al., 2013). This gene encodes the primary
microRNA (pri-miRNA) from which microRNA-137 (miR-137; hsa-miR-
137) is processed. MicroRNAs (miRNAs) are small non-protein coding
RNAs that regulate the expression of other genes by binding to their
mRNA and causing translational repression and/or mRNA destabilization
(Bartel, 2009). miR-137 is expressed in both the developing and adult
brain,where it has been shown to play an important role in the regulation
of cell proliferation and differentiation (Silber et al., 2008; Smrt et al.,
2010; Szulwach et al., 2010; Sun et al., 2011).
Intriguingly, genes that are bioinformatically-predicted to be regu-
lated by miR-137 have been reported to be enriched for association
with schizophrenia (Schizophrenia Psychiatric GWAS Consortium,
2011; Ripke et al., 2013). Genes with predicted miR-137 target sites in-
clude four (TCF4, CACNA1C, CSMD1 and C10orf26 [nowWBP1L]) that aree, Institute of Psychiatry, King's
ur Lane, London SE5 9NU, UK.
. Open access under CC BY-NC-ND licproximal to variants exhibiting genome-wide signiﬁcant association
with schizophrenia (Schizophrenia Psychiatric GWAS Consortium,
2011). The predicted miR-137 target and ﬂanking sequences of these
four genes have been shown to drive lower luciferase activity in the
presence of miR-137 over-expression in HEK293 cells (Kwon et al.,
2013). In addition, luciferase reporter and gene expression assays
have provided evidence that the mRNA product of ZNF804A, containing
another variant showing genome-wide signiﬁcant association with
schizophrenia (Williams et al., 2011), is also a direct target of miR-137
(Kim et al., 2012). These data suggest that genetic inﬂuences on miR-
137 could confer risk for schizophrenia, in part, through a network of
susceptibility genes (Wright et al., 2013).
Although destabilization of target mRNAs is a principal mechanism
by which miRNAs regulate gene expression (Hendrickson et al., 2009;
Guo et al., 2010), to date, only one published study has assessed
genome-wide cellular RNA expression changes following miR-137 ma-
nipulation (Balaguer et al., 2010). In that study, the effects of miR-137
over-expression on global RNA expression were investigated in a
human colon carcinoma cell line. As the extent to which these ﬁndings
can be extrapolated to cells of the human brain is unknown, we have
performed genome-wide RNA proﬁling of a human neural progenitor
cell line followingmiR-137manipulation, in order to identify molecular
pathways throughwhich genetic variation at theMIR137HG locus could
confer susceptibility to schizophrenia.ense.
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2.1. Cell culture
Experimentswere carried out using the CTXOE03 neural cell line ob-
tained from ReNeuron Ltd (www.reneuron.com) under a material
transfer agreement. This is a clinical-grade, karyotypically-normal clon-
al cell line, derived from human fetal cortical neuroepithelium (Pollock
et al., 2006). The CTXOE03 line has been conditionally immortalized by
genomic incorporation of the c-mycERTAM transgene, to stimulate pro-
liferation in the presence of the synthetic drug 4-hydroxy-tamoxifen
(4-OHT). In their proliferative state, CTXOE03 cells stain positive for
nestin, but are negative for both GFAP and β-III tubulin, consistent
with neural progenitor cells (Pollock et al., 2006). Cells were cultured
on laminin-coated T75 ﬂasks using amodiﬁed DMEM:F12media, as de-
scribed previously (Hill et al., 2012).
2.2. Manipulation of miR-137 in cultured cells
Over-expression of miR-137 in CTXOE03 cells was achieved using a
mirVana™ miRNA mimic of the miR-137 precursor (MC10513; Life
Technologies). Inhibition of endogenous miR-137 activity was carried-
out using a mirVana™miRNA inhibitor (MH10513; Life Technologies).
Transfection was performed using the N-TER™ reagent (Sigma) with
mimic and inhibitors at a concentration of 10 nM. Four separate ﬂasks
of seeded cells were transfected with the miR-137 mimic, 4 with the
miR-137 inhibitor and 4 with N-TER™ reagent alone as the negative
control. In order to estimate transfection efﬁciency, an additional T75
ﬂask of seeded cells was transfected with 10nM BLOCK-iT™ Alexa
Fluor® Red Fluorescent oligonucleotide (Life Technologies), using the
sameN-TER™ reagent, and visualized after 24 h byﬂuorescencemicros-
copy. 4-OHT was excluded from the media used for these experiments
so that proliferation was not artiﬁcially stimulated through c-myc
over-expression. Cells were harvested 72 h post-transfection.
2.3. RNA preparation
Pelleted cells were separately homogenized in 1 ml Tri-Reagent®
(Life Technologies) and total RNAextracted according tomanufacturer's
instructions. Residual genomic DNA was removed by addition of 2 μl
Turbo DNA-free™ (Life Technologies) and incubation at 37 °C for 30
min. Integrity of total RNA was assessed using the Agilent 2100
Bioanalyzer (Agilent Technologies). All samples had an RNA integrity
number (RIN) N 9.5.
2.4. Assessment of miR-137 over-expression
Mature miRNA and other small RNA were reverse transcribed from
the four RNA samples in themimic condition and the four RNA samples
in the negative control condition using the TaqMan®MicroRNA reverse
Transcription Kit and TaqMan® MicroRNA assay primers for hsa-miR-
137 (Cat# 000593), hsa-miR-214 (Cat# 002306), hsa-miR-92b
(Cat# 002343) and the endogenous small non-coding RNA controls
U47 (Cat# 001223) and RNU44 (Cat# 001094)(Life Technologies).
The microRNAs miR-214 and miR-92b have previously been shown
to be expressed in human neural progenitor cells (Liu et al., 2012)
and were assayed in order to test whether transfection of the miR-
137 precursor mimic was affecting endogenous microRNA process-
ing. Quantitative PCR (qPCR) was performed on all reverse transcrip-
tion products in duplicate using the TaqMan® MicroRNA assays
listed above and TaqMan® Fast Universal PCR Master mix (Life Tech-
nologies). The expression of mature miR-137, miR-214 and miR-92b
was normalized against that of the U47 and RNU44 controls following
the model of Pfafﬂ (2001) based on observed cycle thresholds and efﬁ-
ciencies for each reaction. The expression of miR-137 in the inhibitorcondition was not assessed as it is designed to bind to (and thus inhibit
the activity of) endogenous miR-137, rather than alter its expression.2.5. Genome-wide RNA expression proﬁling
Biotin-labeled cRNAwas generated from the 4 total RNA samples in
each of the three experimental conditions (mimic, inhibitor and nega-
tive control) using the Illumina TotalPrep-96 RNA ampliﬁcation kit
(Life Technologies). Genome-wide expression proﬁling of each sample
was performed using the Illumina HT-12 v4 BeadChip array (Illumina).
Data were extracted from GenomeStudio software (Illumina) and vari-
ance stabilizing transformation and robust spline normalization applied
using the lumi Bioconductor package (Du et al., 2008). All microarray
data have been submitted to the Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo/), with the accession number GSE49793.
Microarray probes showing differences in expression between the
mimic and negative control conditions and the inhibitor and negative
control conditions were identiﬁed by individual t-tests (two-tailed) at
two levels of statistical signiﬁcance (P b 0.05 and P b 0.01). To limit spu-
rious results arising from low expression genes, probes that were not
detected in at least all four samples of one of the comparison conditions
with a detection P-value N 0.95 were excluded.2.6. Conﬁrmation of downstream gene expression changes
We sought to conﬁrm altered expression of selected genes using
SYBR Green qPCR of cDNA reverse transcribed from the total RNA
assayed bymicroarray. cDNAwas synthesised from each DNase-treated
RNA sample using random decamers and SuperScript® III (Life Technol-
ogies). qPCR primers were designed to target the same exons as themi-
croarray probes showing altered expression (Supplementary Table 1).
Reactions were carried out in a total volume of 20 μl, containing diluted
cDNA, 1× HOT FIREPol® EvaGreen® qPCR Mix (Solis Biodyne, Tartu,
Estonia) and primers at 200 nM, using an MJ Research Chromo 4 (Bio-
Rad) and MJ Opticon Monitor analytic software (Bio-Rad). Given the
small changes in gene expression indicated by the microarray analysis,
we performed 8 technical replicate qPCR reactions for both the target
gene and the internal control gene for each sample and quantiﬁed ex-
pression against a standard curve constructed by serial dilution of
pooled cDNA. GGA1 was identiﬁed as a suitable internal control gene
on the basis of the genome-wide microarray data, where it showed
the least variability (in terms of standard deviation/mean) across all
samples. Target gene expression values (normalized by those of the in-
ternal control) were compared between samples of themimic and neg-
ative control condition or inhibitor and negative control condition by
individual t-tests (2-tailed).2.7. Bioinformatic analyses
Microarray probes at which signiﬁcant gene expression changes
were detected were subject to Gene Ontology (GO) analysis through
the DAVID Bioinformatics Resource 6.7 (Huang et al., 2009) using all bi-
ological process terms in theGOTERM_BP_FAT category. All probeswith
a detection P-value N 0.95 in at least all four samples of one of the com-
parison conditions were used as the background. To test for a general
down-regulation of predicted miR-137 targets in the mimic relative to
the negative control condition, and a general up-regulation of predicted
miR-137 targets in the inhibitor relative to the negative control condi-
tion, fold-changes in the expression of all detected genes that are pre-
dicted to be miR-137 targets by the TargetScan 6.2 program with an
aggregate probability of conserved targeting ≥ 0.9 (Friedman et al.,
2009) were comparedwith fold-changes in the expression of all detect-
ed genes that are not predictedmiR-137 targets using t-tests. All report-
ed P-values are 2-tailed.
Table 1
Biological Process Gene Ontology terms that were signiﬁcantly enriched among genes differentially expressed at P b 0.01 in association with the miR-137 mimic condition.
Gene Ontology term P Genes
GO:0045664
regulation of neuron differentiation
0.00066 TGIF1, BDNF, TIMP2, TTC3, DBN1, CDK5RAP2, CCND2
GO:0050767
regulation of neurogenesis
0.0023 TGIF1, BDNF, TIMP2, TTC3, DBN1, CDK5RAP2, CCND2
GO:0051960
regulation of nervous system development
0.0038 TGIF1, BDNF, TIMP2, TTC3, DBN1, CDK5RAP2, CCND2
GO:0060284
regulation of cell development
0.0069 TGIF1, BDNF, TIMP2, TTC3, DBN1, CDK5RAP2, CCND2
GO:0051789
response to protein stimulus
0.020 TTC3, LOC387820, EIF2AK4, DNAJC4, HSPA4
GO:0010033
response to organic substance
0.022 GNG3, TIMP4, TTC3, LOC387820, EIF2AK4, DNAJC4, HSPA4, FKBP1A, ATP5G3, SREBF2, ASNS, CCND2
GO:0042098
T cell proliferation
0.022 CXCR4, FKBP1A, TNFSF14
GO:0006470
protein amino acid dephosphorylation
0.033 PTPN23, PPP2R3B, DUSP28, PTPN3, PPP1CB
GO:0007411
axon guidance
0.042 CXCR4, BDNF, NRP2, FEZ1
GO:0006986
response to unfolded protein
0.042 LOC387820, EIF2AK4, DNAJC4, HSPA4
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3.1. Over-expression of mature miR-137 in human neural progenitor cells
Transfection efﬁciency, as indexed by uptake of Alexa Fluor® Red
Fluorescent oligonucleotide, was estimated to be N90% (Supplementary
Fig. 1). At harvest, the expression of mature miR-137 was N1000-fold
higher in cells within the mimic condition compared with those in the
negative control condition. Estimates were highly similar following
qPCR normalization using either of the small non-coding RNA internal
controls (RNU44 normalization: mean 1031-fold increase in miR-137
expression, P b 0.0001; U47 normalization: mean 1015-fold increase
in miR-137 expression, P b 0.0001). In contrast, the expression of miR-
214 and miR-92b did not signiﬁcantly differ between the mimic and
negative control conditions when normalized by either of the small
non-coding RNA controls (all P N 0.05), indicating little effect of
transfecting the mimic precursor on the microRNA processing
machinery.3.2. miR-137 manipulations result in small changes in RNA expression
Gene expression differed between the mimic and negative con-
trol conditions at 1080 microarray probes at P b 0.05, and at 202
microarray probes at P b 0.01. Of these, 524 were down-regulated
at P b 0.05 and 96 down-regulated at P b 0.01. Mean fold-changes
in gene expression associated with the miR-137 mimic condition
ranged from 0.70 to 1.48. Gene expression differed between the in-
hibitor and negative control conditions at 1025 microarray probes
at P b 0.05, and at 199 microarray probes at P b 0.01. Of these, 444
were up-regulated at P b 0.05 and 73 up-regulated at P b 0.01.
Mean fold-changes in gene expression associated with the miR-
137 inhibitor condition ranged from 0.71 to 1.47. Only one gene
(BBS7) was differentially expressed in both the mimic versus the
negative control condition and the inhibitor versus the negative
control condition at P b 0.05 in the direction predicted if it were a
direct target of miR-137 (i.e. down-regulated in the mimic and
up-regulated in the inhibitor condition). All probes showing signif-
icant (P b 0.05) differences in gene expression between the mimic
and negative control conditions and the inhibitor and negative
control conditions are listed in Supplementary Tables 2 and 3,
respectively.3.3. Enrichment of gene expression changes involved in neuronal
differentiation after miR-137 over-expression
Gene expression differences between the mimic and negative con-
trol condition at the more stringent threshold of P b 0.01 showed the
most signiﬁcant enrichment within particular Gene Ontology terms.
This set was most signiﬁcantly enriched for genes belonging to the bio-
logical process term ‘regulation of neuron differentiation’ (GO:0045664;
P = 0.00066). The 7 differentially expressed genes belonging to this
term were: BDNF, TGIF1, TIMP2, TTC3, DBN1, CDK5RAP2 and CCND2. All
signiﬁcant (P b 0.05, uncorrected) GO terms for genes differentially
expressed at P b 0.01 in association with the mimic condition are
shown in Table 1. Given that the primary targets of a microRNA mimic
would be predicted to be down-regulated, we then looked for enrich-
ment of Gene Ontology terms in the 96 genes that showed reduced ex-
pression in the mimic relative to the negative control condition at P
b 0.01. All 7 differentially expressed genes belonging to the ‘regulation
of neuron differentiation’ term were down-regulated, and this term
was again the most signiﬁcant (P = 0.000024), surviving correction
for all terms in the GOTERM_BP_FAT category (Bonferroni-corrected
P= 0.014). For differentially expressed genes between the inhibitor
and negative control conditions, the most signiﬁcant biological pro-
cess GO term was ‘aging’ (GO:0007568; P = 0.005) which was
enriched among the gene set detected at P b 0.05. However, neither
this nor any terms enriched in over-expressed genes associated
with the inhibitor condition survived correction for multiple testing
(Bonferroni-corrected P N 0.99).
3.4. Effect of miR-137 manipulation on predicted miR-137 targets
TargetScan predicts 305 miR-137 targets that each had a probability
of conserved targeting N 0.9 (Friedman et al., 2009) and were detected
on the array in all samples of the mimic or negative control conditions.
These showed a very small but highly signiﬁcant down-regulation in the
mimic condition relative to the negative control condition (mean fold-
change = 0.98; P = 0.000019). Of the predicted targets, 13 were
down-regulated at P b 0.05 in the miR-137 mimic condition. These
were ATPAF1, CRKL, CSDA, EFR3A, GNAT1, IDH1, KIAA1671, LBH, MIA3,
PPP1CB, STYX, TULP4 and ZNF148. Four of these genes (CRKL, KIAA1671,
PPP1CB and TULP4) were down-regulated at P b 0.01 in association
with the miR-137 mimic. TargetScan predicts 308 miR-137 targets
that were detected on the array in all samples of the inhibitor or
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between the inhibitor and the negative control condition (mean fold-
change = 0.999; P = 0.46). Of the predicted miR-137 targets, only 3
were up-regulated at P b 0.05 (ESRRG, FAM134C and XRN1) and one
up-regulated at P b 0.01 (XRN1) in association the miR-137 inhibitor
condition.
3.5. Overlapwith genes down-regulated after miR-137 over-expression in a
human colon carcinoma cell line
Balaguer et al. (2010) reported 491 genes that were down-regulated
by N2-fold in an individual sample of a human colon carcinoma cell line
in which miR-137 was over-expressed, compared with an individual
sample of the same cell line after negative control transfection. Of
these, 441 were detected on the array in all samples of the mimic or
negative control conditions in this study. Nineteen of these 441 genes
were down-regulated at P b 0.05 in the miR-137 mimic condition of
this study. These were BDNF, C21ORF66, CSDA, DBN1, DPYSL3, EIF4B,
EP400, FAM3C, FXR1, HSPD1, KIAA1671, LOC642817, PALLD, PCNA, PDHB,
PGAM4, PPP1CB, SLC25A5 and UBE3C. Six of these genes (BDNF, DBN1,
DPYSL3, KIAA1671, PCNA and PPP1CB) were down-regulated at the
more conservative threshold of P b 0.01. Given that BDNF is one of the
genes in the ‘regulation of neuron differentiation’ GO category and
has been implicated in the pathophysiology of psychiatric disorders
(Green et al., 2011; Monteleone et al., 2008; Molendijk et al., 2013)
we further tested its down-regulation by qPCR. This conﬁrmed a signif-
icant down-regulation of BDNF in the miR-137 mimic condition (fold-
change = 0.78, P= 0.03).
3.6. Altered expression of other candidate schizophrenia susceptibility genes
following miR-137 manipulation
In a recently published GWAS analysis (Ripke et al., 2013), 22 inde-
pendent loci showed genome-wide signiﬁcant association with schizo-
phrenia. We explored potential effects of miR-137 manipulation on the
expression of the gene thatwas closest to themost signiﬁcant single nu-
cleotide polymorphism (SNP) at each locus. Nine of these genes (AS3MT,
MAD1L1, CACNB2, SNX19, QPCT, C2orf82, AKT3, SDCCAG8 and C12orf65)
were detected on the array in at least all 4 samples of one of the compar-
ison conditions. Of these,MAD1L1was signiﬁcantly down-regulated in
the miR-137 mimic condition, and this was conﬁrmed by qPCR (fold-
change = 0.72, P = 0.0003). AKT3 was signiﬁcantly up-regulated in
the inhibitor condition (fold-change = 1.07, P = 0.004), but this was
not conﬁrmed by qPCR (fold-change = 0.98, P = 0.76). In addition,
DPYD, a gene that is adjacent to MIR137HG and another candidate
schizophrenia susceptibility gene at that locus (Xu et al., 2012; Ripke
et al., 2013), was signiﬁcantly down-regulated in the miR-137 mimic
condition and this conﬁrmed by qPCR (fold-change = 0.86, P =
0.024). Of the 5 candidate schizophrenia susceptibility genes validated
as miR-137 targets by Kwon et al. (2013) and Kim et al. (2012), only
TCF4 and C10orf26 (nowWBP1L) were detected on the array in at least
all samples of one of the comparison conditions. Neither the miR-137
mimic nor the inhibitor was associated with any effect on TCF4 RNA ex-
pression (mimic fold-change: 1.04, P = 0.44; inhibitor fold-change:
1.02, P= 0.82) or C10orf26 RNA expression (mimic fold-change: 0.95,
P= 0.46; inhibitor fold-change: 0.97, P= 0.61).
4. Discussion
MIR137 is one of the leading candidate schizophrenia susceptibility
genes to arise from large-scale GWAS of the disorder (Schizophrenia
Psychiatric GWAS Consortium, 2011; Ripke et al., 2013). Although bio-
informatic resources are availablewithwhich to predict genes regulated
by individual microRNA, there has been a dearth of empirical data on
genome-wide gene expression changes following miR-137 manipula-
tion. We have therefore performed a genome-wide assessment oftranscriptional changes in a human neural cell line after miR-137
over-expression and inhibition in order to elucidate molecular path-
ways by which genetic perturbation of miR-137 could promote suscep-
tibility to schizophrenia. We ﬁnd that, within these cells, large changes
in miR-137 expression resulted in only minor changes in the RNA ex-
pression of other genes. However, consistentwith bioinformatic predic-
tions and known functional roles ofmiR-137, predicted targets were, en
masse, down-regulated following miR-137 over-expression, and differ-
entially expressed genes were enriched for involvement in neuronal
development. Genes showing signiﬁcant changes in gene expression
included others implicated in the etiology or pathophysiology of
schizophrenia.
The extent to which the gene expression changes we observed will
be relevant to schizophrenia will depend upon the timing and nature
of the risk mechanism associated with genetic variation at the
MIR137HG locus. The SNP at this locus most strongly associated with
schizophrenia in the Psychiatric GWAS Consortium (2011) study is
rs1625579, within an intron of MIR137HG. The most signiﬁcant SNP at
this locus in the more recent study of Ripke et al. (2013) is rs1198588,
located 5′ of MIR137HG, and in strong linkage disequilibrium with
rs1625579 (r2 in CEU sample = 0.78). Homozygosity for the risk allele
of rs1625579 has recently been reported to associate with reduced ex-
pression of the mature miR-137 transcript in dorsolateral prefrontal
cortex from adult control individuals (Guella et al., 2013). Although
we have generated data indicating an association between rs1625579
genotype and the cis-regulation of MIR137HG in human fetal brain
(M.J. Hill & N.J. Bray, unpublished results), the effects of this SNP on
miR-137 expression in neural progenitor cells are currently unknown.
Given the ﬁndings of Guella et al. (2013), future studies might examine
effects of miR-137 manipulation in differentiated cells akin to those of
the adult human brain.
Although a large proportion of the signiﬁcant gene expression
changes we observed will be chance observations, the ﬁndings from
our Gene Ontology analyses suggest that a reasonable number are gen-
uinely the result ofmiR-137manipulation. Consistentwith known func-
tional roles of miR-137 in the mouse brain, genes that were altered
following miR-137 over-expression were signiﬁcantly enriched for in-
volvement in neuronal differentiation. Over-expression of miR-137
has been found to reduce the proliferation and induce premature differ-
entiation of neural stem cells within the embryonic mouse brain (Sun
et al., 2011) and adult subventricular zone (Silber et al., 2008), while
the opposite effects have been reported in neural stem cells of the
adultmurine dentate gyrus (Smrt et al., 2010; Szulwach et al., 2010). Al-
though the aim of the present study was to identify transcriptional con-
sequences of miR-137 manipulation, future studies could explore the
physiological effects of these manipulations in cells from the human
brain. Effects of miR-137 perturbation on brain development could ac-
count for reported associations between the rs1625579 risk allele and
regional brain volumes as well as earlier age of onset in schizophrenia
(Lett et al., 2013).
One of the seven differentially expressed genes associated with
the miR-137 mimic and annotated as belonging to the GO term ‘reg-
ulation of neuron differentiation’ is BDNF, encoding brain-derived
neurotrophic factor, a molecule that has been reported to be reduced
in the serum of patients with schizophrenia (Green et al., 2011) and
other psychiatric disorders (Monteleone et al., 2008; Molendijk
et al., 2013). Signiﬁcant down-regulation of BDNF RNA after miR-
137 over-expression was conﬁrmed by qPCR. Only two of the
microRNA target prediction programs included in the miRecords da-
tabase (Xiao et al., 2009) – PITA (Kertesz et al., 2007) and RNAHybrid
(Krüger and Rehmsmeier, 2006) – predict BDNF as a primary target
of miR-137. However, that BDNF RNA has also been found to be re-
duced following miR-137 over-expression in another human cell
line (Balaguer et al., 2010) suggests that, even if it is not a direct tar-
get, it does indeed serve as a downstream effector of miR-137
function.
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genes that were differentially expressed, ourmethodology does not dis-
tinguish between gene expression changes resulting from the primary
actions of miR-137 or their downstream consequences. It is likely that
these will be differentially detected depending on the time-point at
which the RNA is assayed, with later time-points detecting a greater
proportion of secondary gene expression changes. Technology is now
available with which to experimentally screen a large number of genic
sequences to identify likely targets of individual miRNA (Gäken et al.,
2012). However, downstream effects on gene expression are also
important to identify since they might better reﬂect the cellular
consequences of miR-137 manipulation as well as including addi-
tional molecular changes of potential relevance to schizophrenia
pathogenesis.
Previous studies have reported that bioinformatically-predicted
miR-137 targets are enriched for association with schizophrenia
(Schizophrenia Psychiatric GWAS Consortium, 2011; Ripke et al.,
2013) and several genes at loci exhibiting genome-wide signiﬁcant
association with the disorder have been validated as miR-137 tar-
gets by reporter gene assays (Kim et al., 2012; Kwon et al., 2013).
Most recently, Ripke et al. (2013) cite unpublished ﬁndings from
a similar study to our own in which miR-137 was over-expressed
in human neural stem cells and where an enrichment of schizo-
phrenia association signals in down-regulated genes was observed
(A.L. Collins, Y. Kim, R. Bloom, D. Rubinow, W. Sun et al., unpub-
lished results). Of genes at genome-wide signiﬁcant risk loci for
schizophrenia that were sufﬁciently expressed in our cells, we
were able to conﬁrm signiﬁcant down-regulation of MAD1L1 and
DPYD in association with miR-137 over-expression. Although
TargetScan predicts neither gene as a direct miR-137 target, the
known role of MAD1L1 in cell proliferation (e.g. Rottmann et al.,
2005) makes it a good candidate for mediating miR-137 action.
Our ﬁndings also suggest that effects of schizophrenia risk varia-
tion on miR-137 expression (Guella et al., 2013) could have a
downstream effect on the expression of DPYD, another candidate
schizophrenia susceptibility gene at the MIR137HG locus (Xu et al.,
2012; Ripke et al., 2013).
We observed no signiﬁcant effect of miR-137 manipulation on the
RNA expression of TCF4 or C10orf26, the two genes at genome-wide sig-
niﬁcant schizophrenia risk loci that have been previously validated as
miR-137 targets (Kwon et al., 2013) and which were sufﬁciently
expressed in our cells to be tested. Although mRNA destabilization is
now considered to be a principle mechanism by which microRNA re-
press their targets (Guo et al., 2010), it is possible that the protein ex-
pression of these and other predicted miR-137 targets is regulated by
translational repression in the absence of effects on mRNA levels. The
application of proteomic technologies (e.g. Gold et al., 2012) following
cellular miR-137 manipulation could address this question.
The changes in RNA expressionwe observed followingmiR-137ma-
nipulation were very small. Although Balaguer et al. (2010) report a
number of genes showing N2-fold expression differences following
miR-137 over-expression in a human carcinoma cell line, it should be
noted that this was in a comparison between a single control sample
and single sample in which miR-137 was over-expressed, whereas we
report themean fold-change of expression over control from the 4 sam-
ples in each condition. The expression of any given gene will be deter-
mined by a multitude of regulatory factors, which might restore
mRNA levels in spite of large changes in the expression of an interacting
microRNA. These factors are likely to differ between cell types, such that
some targets might be more vulnerable to microRNA manipulation in
certain cells. In addition, genetic variation in the functioning of these
targets and their other regulators might lead to variable effects of
miR-137 perturbation between individuals.
In summary, we have produced a genome-wide assessment of
transcriptional changes following miR-137 manipulation in a
human neural progenitor line. We ﬁnd altered RNA expression ofgenes involved in neuronal development, and a general down-
regulation of bioinformatically-predicted miR-137 targets, following
miR-137 over-expression. Differentially expressed genes included
others implicated in the etiology or pathophysiology of schizophre-
nia. As well as illuminating molecular risk mechanisms associated
with individual susceptibility genes, studies such as this will be im-
portant in establishing the extent to which these genes converge
into shared biological pathways.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.schres.2014.01.034.
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